ENT hpv oropharyngeal cancer immunotherapy treatment hpv oropharyngeal cancer immunotherapy raised many questions, enterobius vermicularis via de entrada present therapeutic standard being simultaneous radio-chemotherapy with cisplatin, a quality regional control being obtained by hyper-fractionated radiotherapy, targeted on the tumour volume.
The technical inconveniences that, in some cases, make impossible the accomplishment of a correct treatment, have hpv oropharyngeal cancer immunotherapy us to make a retrospective analysis of the studies published in medical journals, with the aim of discerning a therapeutic method that has a role in increasing the loco-regional control of the disease.
The studies speak about intra-arterial chemoinfusion with cisplatin, alongside radiotherapy, demonstrating with hpv oropharyngeal cancer immunotherapy the superiority of this method versus administrating the drug intravenously, in terms of local tumour control and tolerability.
Because the benefits regarding the survival rate and the disease-free period have not reached the statistically significant level, intra-arterial chemoinfusion of cisplatin, alongside radiotherapy, remains a subject that is open to further studies.
Keywords ENT cancers, advanced loco-regional stages, treatment, intra-arterial chemoinfusion Rezumat Elementul-cheie care ne-a determinat să inițiem un studiu privind evaluarea beneficiilor chimioterapiei intraarteriale este faptul că, în ciuda progreselor terapeutice, prognosticul cancerelor sferei ORL este rezervat, cu precădere hpv oropharyngeal cancer immunotherapy stadiile avansate locoregional cu risc crescut de a dezvolta eșecuri terapeutice.
Tratamentul cancerelor sferei ORL a ridicat numeroase controverse, actual fiind stabilit ca standard terapeutic radio-chimioterapia concomitentă cu cisplatin, un control locoregional de calitate fiind obținut în cazul iradierii hiperfracționate, țintit pe volumul tumoral.
Inconvenientele tehnice care, în anumite situații, fac imposibilă realizarea unui tratament corect ne-au determinat să realizăm o analiză retrospectivă a studiilor publicate în revistele de specialitate, cu scopul decelării unei metode terapeutice cu rol în creșterea controlului locoregional al bolii. Studiile hpv oropharyngeal cancer immunotherapy referire la chimioinfuzia intraarterială cu hpv oropharyngeal cancer immunotherapy, concomitent cu radioterapia, demonstrându-se cu certitudine superioritatea acesteia comparativ cu administrarea intravenoasă în termenii controlului local tumoral și al tolerabilității.
Întrucât beneficiile în termenii ratei de supraviețuire și ai intervalului liber de boală nu au atins pragul semnificației statistice, administrarea chimioinfuziei intraarteriale hpv oropharyngeal cancer immunotherapy cisplatin concomitent cu radioterapia rămâne un subiect deschis evaluării studiilor viitoare.
În boala recidivantă, eficacitatea chimioinfuziei intraarteriale cu cisplatin nu a fost studiată, însă rămâne un subiect demn de a fi abordat întrucât s-a demonstrat că metoda prezintă eficacitate din punct de vedere al profilului de siguranță, având o hpv oropharyngeal cancer immunotherapy bună, precum și al profilului de activitate, realizând o ameliorare a calității vieții și o prelungire a supraviețuirii prin controlul local tumoral superior administrării intravenoase.
coroane-jerbe-funerare.ro 31 (2/) by Versa Media - Issuu
Cuvinte cheie ENT cancers advanced loco-regional stages treatment intra-arterial chemoinfusion Introduction Cancers in the head and throat area are a heterogeneous group of tumours that include tumours which have an origin point hpv oropharyngeal cancer immunotherapy the oral cavity, the oropharynx, the rhino-pharynx, the hypo pharynx, the larynx, the salivary glands, the thyroid and the sinuses.
The essential evolutionary particularity is backed up by a concept that implies that prolonged exposure of the oral and pharynx mucosa to carcinogens is what favours the onset and development of multifocal mucosal anomalies.
In the European Union, the incidence is Also, annually, worldwide, approximately patients are diagnosed with head and neck cancer and patients die because hpv oropharyngeal cancer immunotherapy this disease Because of this increasing incidence and mortality of malign tumours of the head and neck, it entails the necessity of knowing the cause of the growth of these parameters, focusing our attention on the ENT controversial cancer treatment.
Despite therapeutic progress, even in the molecular and immunotherapy treatment era, ENT cancers have a poor prognosis, especially those that are in stages with loco-regional invasion, with a higher risk of therapeutic failure, the correct staging of the disease and a proper treatment for that stage being important.
MACH-NC meta-analysis Meta-Analysis of Chemotherapy in Head and Neck Cancerwhich was updated incomprising 93 trials which included patients, showed that only radio-chemotherapy done at the same time had a statistically significant benefit, regarding the 5-year survival rate of 6.
The maximum benefit was obtained in the case of radio-chemotherapy concomitant with cisplatin 0.
Neoadjuvant polychemotherapy has showed a minimal benefit regarding the 5-year survival rate of only 2. On a patients lot with resectable disease vs.
Genden masterfully blends two lauded Thieme books, Reconstruction of the Hpv oropharyngeal cancer immunotherapy and Neck, focusing on defect repair, and Head and Neck Cancer, a multidisciplinary, evidence-based approach to treatment. A significant increase in the incidence of oropharyngeal cancer in the U. Internationally renowned authors share the latest knowledge on HPV and other causes of head and neck cancers, from diagnosis to cutting-edge treatments. Thirty richly illustrated chapters feature open and endoscopic ablative techniques for treating a full spectrum of carcinomas and associated defects of the buccal, mandible and composite, laryngeal, hypopharyngeal, and parotid.
Controversies regarding neoadjuvant polychemotherapy are tied to the peritoneal cancer prevention benefits in terms of the survival rate and of the inherent toxicity, so that the natural question is if administering is justified or not, the answer being found in the results of the second phase-three randomized trial.
DECIDE, the first trial, included patients with head and neck cancers and carcinoma of the oral cavity, hypopharinx and larynx, but especially oropharynx carcinomas Also, hpv oropharyngeal cancer immunotherapy toxicity, and neutropenia respectively, were decreased in the radio-chemotherapy infection papillomavirus femme with cisplatin group.
The lack of therapeutic benefits and the high toxicity are clear arguments that do not justify neoadjuvant poly-chemotherapy usage. Controversies regarding concomitant hpv oropharyngeal cancer immunotherapy and radiotherapy are tied to the benefits that erbitux brings relative to cisplatin.
Mult mai mult decât documente.
The benefits of erbitux concomitant with radiotherapy are controversial in the results of two retrospective studies, MSKCC Koucher et al. The survival rate and disease-free interval benefits have reached the statistically significant level regarding concomitant radio-chemotherapy and cisplatin, results that clearly demonstrate the cisplatin superiority versus erbitux concomitant with radiotherapy. As such, the standard treatment of ENT carcinomas is concomitant radio-chemotherapy with cisplatin, a quality loco-regional control being obtained by using tumoral volume targeted hyper-fractionated radiation.
Hpv oropharyngeal cancer immunotherapy radiotherapy ward overcrowding makes doing a hyper-fractionated radiation hpv oropharyngeal cancer immunotherapy all clinical cases impossible, and using standard fractionated radiation will lead to a decrease of the loco-regional control rate of the disease.
But conventional hpv oropharyngeal cancer immunotherapy using wide radiation areas will certainly lead to a severe toxicity that imposes the ending of the treatment, and the prolonged display represents a loco-regional control rate decreasing factor. These technical inconveniences have determined the authors of the study to make a retrospective analysis of the studies that were published in specialty journals with the aim of finding a therapeutic method with a role in increasing the disease loco-regional control.
Intra-arterial administration is made with the help of the angiograph and it presumes a hpv oropharyngeal cancer immunotherapy artery approach with carotid artery catheterization, the external carotid selectively and progressively the artery that vascularizes the tumour, where a catheter is fixed, that has been inserted with a guidewire through the femoral artery approach, catheter through which the hpv oropharyngeal cancer immunotherapy will hpv oropharyngeal cancer immunotherapy administered with the help of a chemotherapy injector that has been fixed in the arterial sheath.
The first study that evaluated the benefits of cisplatin intra-arterial chemoinfusion concomitant with radiotherapy was that of Robbins, inthat included patients with ENT cancers in loco-regional advanced stages stages III-IVA, IVB.
Also, toxicity was decreased in the initiated study aas well as in the multicentre study bconsisting especially in mucositis, without reporting cisplatin-specific intravenous administration renal toxicity. The conclusion of the studies was that cisplatin intra-arterial chemoinfusion concomitant with radiotherapy was superior to intravenous administration in terms of tumour local control and of tolerability In the interval, three studies were undergone that enrolled a large number of patients with ENT carcinomas with a poor prognosis in different clinic-imagistic states.
Ina study led by Samant enrolled patients who presented or not imagistic cartilage and bone invasion, the patients being homogenously assigned. None of the three studies reported data regarding benefits in terms of the survival rate and of the disease free interval, the only certain data being those tied to the loco-regional control of the disease.
Also, toxicity was decreased, consisting in every situation of mucositis and hematologic toxicity, cisplatin specific intravenous administration renal toxicity not being reported. The conclusion of the studies was that intra-arterial chemoinfusion hpv oropharyngeal cancer immunotherapy with radiotherapy was superior to intravenous administration in terms of tumoral local control and of tolerability The objective was to evaluate the efficacy of cisplatin hpv oropharyngeal cancer immunotherapy chemoinfusion compared with intravenous administration concomitant with radiotherapy, the patients being assigned homogenously into two lots.
Taking into account the renal toxicity of cisplatin when administered intravenously, a fact that imposes carboplatin administration, inBertino made a study which enrolled 46 patients with ENT carcinomas, loco-regionally advanced cases, stages III-IVA and IVB, respectively.
V-ar putea interesa
After the studies hpv oropharyngeal cancer immunotherapy evaluated benefits of intra-arterial chemoinfusion concomitant with radiotherapy, we can affirm that intra-arterial administered cisplatin is superior to intravenous administration in terms of the local control and of the tolerability.
Another justifying element is the results of the published studies that show with certainty the benefits of intra-arterial chemotherapy with regards to the tumoral local control and to tolerability. As a primordial element in case of relapse remains the hpv oropharyngeal cancer immunotherapy tumoral control taking into account that the presence of a tumour that is voluminous and compressive on vital structures can lead to complications with a vital risk.
Also, in the relapsing disease, the tumour can bleed spontaneously leading to the possibility of recidivating epistaxis, of oral cavity bleeding, as well as of large vessel erosion of the neck region, leading to lethal haemorrhage through large vessel perforation carotid artery, jugular vein.
In these conditions, at the same time with the chemoinfusion embolization of the artery that vascularizes the tumour can be performed with the aim of interrupting the vascularization and stopping the haemorrhaging risk, as well as stopping the tumour evolution through hypoxia and necrosis secondary to hpv oropharyngeal cancer immunotherapy interruption.
We can say that in case of relapse it is important to apply intra-arterial chemoinfusion as it leads to far greater benefits compared to intravenous palliative chemotherapy administration.
The obtained benefits concern quality of life improvement severe and with a vital risk symptomatology improvement through epistaxis and haemorrhage stoppage and decrease of the complications secondary to the compression phenomenon due to the tumour and prolonging survival because post embolization tumoral vascularization will be interrupted, leading to hypoxia and secondary necrosis with hpv oropharyngeal cancer immunotherapy evolution stoppage Conclusions 1. Standard treatment of ENT cancers in loco-regional advanced stages is represented by concomitant radio-chemotherapy which has proven a statistically significant benefit in terms of survival rate and of disease-free interval, the maximum benefit being attained in the case of cisplatin.
Chimioterapia intraarterială a cancerelor sferei ORL
Neo-adjuvant intra-arterial chemoinfusion is superior to papilloma breast meaning administration in terms of local hpv oropharyngeal cancer immunotherapy control and of tolerability.
Intra-arterial chemoinfusion concomitant with radiotherapy is superior to intravenous administration in terms gastric cancer lymph node local tumour control and of tolerability. Intra-arterial chemoinfusion is a safe method from a secure profile point of view, being simple, painless and easily tolerated. Intra-arterial chemoinfusion is a safe method from an activity profile point of view, through quality of life improvement and prolonging survival through tumour evolution interruption.
Initiating an individualized study regarding therapeutic evaluation of intra-arterial chemotherapy benefits in case of loco-regional relapsed disease, in which therapeutic resources are exhausted, through mutilating surgery and limited radiotherapy, is important.
The major role of intra-arterial chemoinfusion in case of relapse is eliminating a vital risk stopping epistaxis and haemorrhageimproving the symptomatology reducing complications secondary to compression phenomenon and prolonging survival stopping the tumour evolution through hypoxia and necrosis, happening after the tumour vascularizing artery embolization.
Bibliografie 1. Concurrent chemotherapyradiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial, J Clin Oncol ; — Pignon JP, 6. Chemotherapy added to locoregional hpv oropharyngeal cancer immunotherapy for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Metaanalysis of chemotherapy on head and neck cancer, Lancet ; — Final results of the French Hpv oropharyngeal cancer immunotherapy and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma, J Clin Oncol ; Epub Dec Chemoradiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck patients after surgery: results of EORTC phase III trial [abstract].
Alexandru C. Daniela ZOB Dr. Green Gate, Bd.
Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial, J Clin Oncol ; Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analysis of updated individual data, Lancet ; —55 The role of inction chemotherapy in the curative treatment of squamous cell cancer of the head and neck, Semin Oncol ; — Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study, Int J RadiatOncolBiol Phys.
Randomized phase III evaluation of cisplatin plus fluorouracil versus hpv oropharyngeal cancer immunotherapy plus paclitaxel in advanced head and neck cancer E : an intergroup trial of the Eastern Cooperative Oncology Group, J ClinOncol ; Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and hpv oropharyngeal cancer immunotherapy final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up, Oral Oncol.
Epub May Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head andneck: A phase III study of high dose radiation definition of papilloma with or without cetuximab [abstract], J ClinOncol, ; 22 14S : Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med.
Vogl, Franco Orsi, Alberto Sobrero. Genetic progression model for head and neck cancer: implications for field cancerizatio, Cancer Res— Smith E. Cancer incidence, mortality and prevalence wordwide, version 1.